Product Information
BROMFENAC SODIUM 0.07% EYE DRP is a generic product labeled by Lupin Pharmaceuticals Inc., priced at $13.2497 per ML under NDC 68180043302. Its NADAC has been published 129 times since Apr 17, 2024.
FDA first approved this application on Nov 22, 2023. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
.805 mg/mL
Manufacturer
Lupin Pharmaceuticals Inc.NDC
68180043302
Classification
Generic
Dosage Form
SOLUTION/ DROPS
Route
OPHTHALMIC
Effective Date
9/23/2026
Active Ingredients
BROMFENAC SODIUMApproval Type
Generic (ANDA)
FDA Application
ANDA206027FDA Approved
11/22/2023
TE Code
AB
On Market Since
1/8/2024
Pharmacological Classes
Price Statistics
The NADAC for BROMFENAC SODIUM 0.07% EYE DRP has been published 129 times since Apr 17, 2024, and over the history we have for it it has declined 75.6%. The table below summarizes its recorded NADAC range and movement.
| Current price | $13.2497 per ML |
|---|---|
| All-time high | $75.5251 (Jul 10, 2024) |
| All-time low | $11.7673 (Apr 22, 2026) |
| 52-week high | $15.1836 |
| 52-week low | $11.7673 |
| Median price | $15.4792 |
| Average price | $24.7794 |
| Largest weekly change | -53.9% (Nov 20, 2024) |
| Weeks tracked | 129 |
| Tracking since | Apr 17, 2024 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the bromfenac sodium market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Lupin Pharmaceuticals Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
bromfenac sodium market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Nonsteroidal Anti-inflammatory Drug class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of BROMFENAC SODIUM 0.07% EYE DRP?
The current National Average Drug Acquisition Cost (NADAC) for BROMFENAC SODIUM 0.07% EYE DRP, manufactured by Lupin Pharmaceuticals Inc., is $13.2497 per ML (NDC 68180043302), effective Sep 30, 2026.
How has the price of BROMFENAC SODIUM 0.07% EYE DRP changed over time?
Over the history we have for it, the NADAC for BROMFENAC SODIUM 0.07% EYE DRP has declined 75.6%. It has been tracked across 129 weekly CMS publications since Apr 17, 2024.
What are the highest and lowest recorded NADAC prices for BROMFENAC SODIUM 0.07% EYE DRP?
Since Apr 17, 2024, the NADAC for BROMFENAC SODIUM 0.07% EYE DRP has ranged from a low of $11.7673 (Apr 22, 2026) to a high of $75.5251 (Jul 10, 2024), with a median of $15.4792 per ML.
Are there cheaper alternatives to BROMFENAC SODIUM 0.07% EYE DRP?
No other NADAC-published product currently shares the active ingredient and strength of BROMFENAC SODIUM 0.07% EYE DRP in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures BROMFENAC SODIUM 0.07% EYE DRP?
BROMFENAC SODIUM 0.07% EYE DRP (NDC 68180043302) is labeled by Lupin Pharmaceuticals Inc., and CMS classifies it as a generic product.